DYANAVEL XR CII
Generic Name and Formulations:
Amphetamine 2.5mg/mL; ext-rel oral susp; bubblegum flavor.
Tris Pharma Inc.
Indications for DYANAVEL XR:
Attention deficit hyperactivity disorder.
Adults and Children:
Do not substitute for other amphetamine products on a mg-per-mg basis. <6yrs: not established. Individualize. Take in the morning. ≥6yrs: initially 2.5mg or 5mg once daily; may increase by 2.5mg–10mg/day every 4–7 days; max 20mg/day.
During or within 14 days of MAOIs.
Abuse and dependence.
Abuse potential (monitor). Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for serotonin syndrome; discontinue if occurs. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor BP, HR, growth in children. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy: monitor for neonatal withdrawal symptoms. Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, busprione, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by urinary alkalinizers (eg, sodium bicarbonate, acetazolamide); avoid. Antagonized by acidifiers (eg, ascorbic acid). May potentiate TCAs or sympathomimetics; adjust dose or use alternatives. May interfere with urinary steroid tests.
Dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, tachycardia; hypertension.
Clinical Pain Advisor Articles
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Greater Temporal Summation of Pain in HIV With Chronic Pain
- FDA Warns Two Companies About Bogus Opioid Addiction Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- A Potential Biomarker for Predicting Antibody Treatment Efficacy in Migraine